Dataset Information

Nostoc sphaeroids Kutz ameliorates hyperlipidemia and maintains the intestinal barrier and gut microbiota composition of high-fat diet mice.

ABSTRACT: Hyperlipidemia is associated with chronic inflammation and intestinal dysbiosis. The purpose of this study was to investigate the protective effect of Nostoc sphaeroids Kütz (NO) on diet-induced hyperlipidemia in mice. Experimental animals received a high-fat diet (HFD) for 4 weeks, then an HFD supplemented with 2.5% or 7.5% NO for 6 weeks. HFD-fed mice exhibited a significant increase in serum total cholesterol, triglycerides, and low-density lipid cholesterol, and a decrease in high-density lipid cholesterol. NO supplementation was associated with significantly lower dyslipidemia, decreased intestinal inflammation, and inhibition of toll-like receptor 4 gene repression in HFD-fed mice. Results suggest that NO treatment protected the integrity of the intestinal barrier. NO treatment was also associated with significant changes in the intestinal microbiota induced by HFD and an increase in the Firmicutes-to-Bacteroidetes ratio. Furthermore, NO treatment was also inversely correlated with mice obesity and hyperlipidemia NO and was associated with no significant in fecal short-chain fatty acids. In conclusion, NO significantly ameliorated hyperlipidemia induced by a HFD in mice, potentially via a decrease intestinal inflammation, increase in intestinal barrier integrity, and amelioration in the gut microbiota.

SUBMITTER: Wei F

PROVIDER: S-EPMC7215204 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

<i>Nostoc sphaeroids</i> Kütz ameliorates hyperlipidemia and maintains the intestinal barrier and gut microbiota composition of high-fat diet mice.

Wei Fenfen F Liu Yinlu Y Bi Cuicui C Chen Sheng S Wang Yulan Y Zhang Bo B

Food science & nutrition 20200414 5

Hyperlipidemia is associated with chronic inflammation and intestinal dysbiosis. The purpose of this study was to investigate the protective effect of <i>Nostoc sphaeroids</i> Kütz (NO) on diet-induced hyperlipidemia in mice. Experimental animals received a high-fat diet (HFD) for 4 weeks, then an HFD supplemented with 2.5% or 7.5% NO for 6 weeks. HFD-fed mice exhibited a significant increase in serum total cholesterol, triglycerides, and low-density lipid cholesterol, and a decrease in high-den ...[more]

PMID: 32405392

Similar Datasets

Project description:Background: A high-fat Western diet is a risk factor for obesity and steatosis. Reducing intestinal absorption of a high-fat diet (HFD) is a feasible strategy to control obesity. Sulfosuccinimidyl oleate (SSO) inhibits intestinal fatty acid transport. Therefore, the aim of this study was to investigate the effects of SSO on HFD-induced glucose and lipid metabolism in mice and its possible underlying mechanisms. Methods: Male C57/BL were fed a HFD (60% calories) for 12 weeks and were administered an oral dose of SSO (50 mg/kg/day). The expression of lipid absorption genes (CD36, MTTP, and DGAT1) and the serum levels of triglycerides (TGs), total cholesterol (TC), and free fatty acids (FFAs) were detected. Lipid distribution in the liver was detected by oil red and hematoxylin and eosin staining. In addition, serum levels of inflammatory factors, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were measured to detect side effects. Results: SSO was effective in the treatment of obesity and metabolic syndrome induced by HFD in mice. It attenuated the assembly of intestinal epithelial chylomicrons by inhibiting intestinal epithelial transport and absorption of fatty acids, thereby reducing the gene expression levels of MTTP and DGAT1, resulting in decreased plasma TG and FFA levels. At the same time, it inhibited the transport of fatty acids in the liver and improved the steatosis induced by a HFD. The results of oil red staining showed that SSO treatment can reduce lipid accumulation in the liver by 70%, with no drug-induced liver injury detected on the basis of interleukin-6, C-reactive protein, ALT, and AST levels. In addition, SSO treatment significantly improved insulin resistance, decreased fasting blood glucose levels, and improved glucose tolerance in HFD-fed mice. Conclusion: SSO is effective in the treatment of obesity and metabolic syndrome induced by a HFD in mice. SSO reduces intestinal fatty acid absorption by reducing the inhibition of intestinal CD36 expression, followed by decreased TG and FFA levels, which attenuates HFD-induced fatty liver.

Dataset Information

Nostoc sphaeroids Kutz ameliorates hyperlipidemia and maintains the intestinal barrier and gut microbiota composition of high-fat diet mice.

Publications

<i>Nostoc sphaeroids</i> Kütz ameliorates hyperlipidemia and maintains the intestinal barrier and gut microbiota composition of high-fat diet mice.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets